MRK

Merck & Company Inc
NYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL

Key Statistics

Market Cap
$364.26B
P/E Ratio
147.76
EPS
$1.00
Beta
0.12
52W High
$156.00
52W Low
$89.48
50-Day MA
$146.13
200-Day MA
$128.65
Dividend Yield
2.29%
Profit Margin
3.64%
Forward P/E
16.18
PEG Ratio
3.56

About Merck & Company Inc

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$67.38B
Gross Profit (TTM)$50.67B
EBITDA$29.49B
Operating Margin35.20%
Return on Equity5.06%
Return on Assets11.30%
Revenue/Share (TTM)$27.24
Book Value$18.20
Price-to-Book8.07
Price-to-Sales (TTM)5.41
EV/Revenue6.03
EV/EBITDA28.89
Quarterly Earnings Growth (YoY)-12.00%
Quarterly Revenue Growth (YoY)4.70%
Shares Outstanding$2.47B
Float$2.46B
% Insiders0.06%
% Institutions82.29%

Historical Volatility

HV 10-Day
28.88%
HV 20-Day
32.43%
HV 30-Day
32.43%
HV 60-Day
28.10%
HV Rank
79.4%

Volatility is currently contracting

Analyst Ratings

Consensus ($161.53 target)
5
Strong Buy
14
Buy
9
Hold

Latest News

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV dis.

Business Wire11/13/2026Neutral
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p.

Business Wire11/13/2026Neutral
3 Pharmaceutical Stocks That Offer Safety and Growth

Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.

MarketBeat11/12/2026Positive
What Merck KGaA (MRK) Said on Its Q3 Earnings Call

Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio.

MarketBeat11/12/2026Neutral
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult tre.

Business Wire11/10/2026Neutral
INVA or MRK: Which Is the Better Value Stock Right Now?

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research11/9/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRK and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/14/2026